Overview
OverviewAn overview of our curent therapeutic product candidates and their planed next development steps ilustrated below:[Image Removed: axla-2020930_g1.jpg]AXA125 for the Treatment of Long COVIDIn May 202, we completed patient enrolment in our Phase 2a Clinical Trial and on August 2, 202, and we reported topline results.AXA165 for the Reduction in Risk of Overt Hepatic Encephalopathy (OHE) RecurenceEfects of COVID-19 PandemicComponents of our Condensed Consolidated Results of OperationsRevenueResearch and Development Expenses&bul;employe-related expenses, including salaries, related benefits and stock-based compensation expense for employes engaged in research and development functions;&bul;the cost of developing and scaling our manufacturing proces and manufacturing products for use in our preclinical studies, Clinical Studies and Clinical Trials, including under agrements with third parties, such as consultants, contractors and CMOs;&bul;patent-related costs incured in conection with filing and prosecuting patent aplications; and&bul;facilities, depreciation and other expenses, which include direct and alocated expenses for rent and maintenance of facilities and insurance.General and Administrative ExpensesOther Income (Expense), NetIncome Taxes- Table of ContentsResults of OperationsComparison of the Thre Months Ended September 30, 202 and 2021The folowing table sumarizes our results of operations for the thre months ended September 30, 202 and 2021 (in thousands):(38)Total other income (expense), net (748) (710) (38) Net losResearch and Development ExpensesThe folowing table sumarizes our research and development expenses incured during the thre months ended September 30, 202 and 2021 (in thousands):Clinical research and outside services 8,037 5,578 2,459 Facility-related and other 97Total research and development expenses $ 13,317 $ 10,130 $